ArticleScientific reports2025
CKAP2, miR-941, miR-548 and LINC02577 as biomarkers for early diagnosis in colorectal cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic and therapeutic implications of PSMD14 in hepatocellular carcinoma: an integrative analysis of transcriptomic and single-cell profiles.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a leading cause of cancer-related mortality globally, necessitating biomarkers for early detection and targeted therapies. We integrated RNA-seq (GSE180440) weighted gene co-expression analysis with experimental validation to identify coding and long non-coding RNA biomarkers associated with tumor biology and treatment response. Bioinformatics analysis of GSE180440 dataset (145 tumor, 45 normal samples) identified differentially expressed genes (DEGs) and lncRNAs (DELs) using DESeq2. Weighted gene co-expression network analysis (WGCNA) identified modules linked to CRC traits. Functional enrichment, protein-protein interaction (PPI), and miRNA-gene networks were constructed. Validation used TCGA-COAD and RT-qPCR on 61 paired CRC samples. Diagnostic performance was assessed by ROC/AUC (pROC). Drug-response and survival analyses were performed with GEPIA3. From 672 DEGs and WGCNA, LINC02577, LINC00294 and CKAP2 emerged as hub candidates together with miR-548k and miR-941. In TCGA-COAD CKAP2 (log2FC = 1.501, P < 0.001) and LINC02577 (log2FC = 6.676, P < 0.001) were significantly upregulated, while LINC00294 was downregulated (log2FC = - 1.104, P < 0.001). Diagnostic AUCs (tumor vs. normal) were: LINC02577 0.982, CKAP2 0.797 and CEA 0.663; LINC00294 showed poor discrimination (AUC = 0.055). In our cohort CKAP2 associated with tumor size > 5 cm (P = 0.025, AUC = 0.667) and LINC02577 associated with nodal involvement in females (P = 0.028, AUC = 0.736). miR-548k overexpression correlated with early invasion (P = 0.044, AUC = 0.667). LINC02577 expression was higher in patients with progressive disease after leucovorin-containing regimens (P = 0.009). None of the selected genes were prognostic for overall survival. We identified CKAP2, LINC02577, miR-941, and miR-548k as key biomarkers with distinct expression patterns in early-stage CRC. Their altered expression in small, early-stage tumors reveales their potential for early CRC detection. LINC02577 and CKAP2 show strong diagnostic utility (AUCs 0.982 and 0.797) outperforming CEA, and LINC02577 may predict poor response to leucovorin-containing therapy (P = 0.009). These candidates warrant functional studies to define mechanisms and evaluate clinical applicability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.